Endeavor Biomedicines is currently conducting a Phase 2 Clinical Trial: A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations.
Am I eligible for the research study?
For this study, only people who are being treated for advanced cancer and have the PTCH1 LOF mutation are eligible.
Click here to register with xINFORM and see if you are eligible.
Check out our feature segment on The Balancing Act Presents: The Future of Cancer Treatments… How Next Generation Sequencing can optimize treatment options for patients with solid tumors: